产品
编 号：F754008
产品类型
规格
价格
是否有货
结构图
CAS No: 2599039-60-6
产品详情
生物活性：
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model.
体内研究：
Ogalvibart (C-135-LS; 10 mg/kg; 感染前 75 天给药) 联合 10 mg/kg 的 C144LS 时，能有效阻断恒河猴疾病模型中 COVID19 的发展。Animal Model:Rhesus macaques (3-11 years old).
Dosage:10 mg/kg (in combination with 10 mg/kg C144LS)
Administration:75 days before infection
Result:Protected a subset of animals whose infectious challenge was 75 days post administration from disease.
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model.
体内研究：
Ogalvibart (C-135-LS; 10 mg/kg; 感染前 75 天给药) 联合 10 mg/kg 的 C144LS 时，能有效阻断恒河猴疾病模型中 COVID19 的发展。Animal Model:Rhesus macaques (3-11 years old).
Dosage:10 mg/kg (in combination with 10 mg/kg C144LS)
Administration:75 days before infection
Result:Protected a subset of animals whose infectious challenge was 75 days post administration from disease.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备